Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biotech Vaneck ETF (BBH)

Biotech Vaneck ETF (BBH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 503,915,400
  • Shares Outstanding, K 2,797
  • 60-Month Beta 1.01
Trade BBH with:
  • Price/Earnings ttm 25.85
  • Annual Dividend & Yield 0.61
  • Most Recent Dividend 0.608
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
166.87 +8.45%
on 01/04/21
182.00 -0.57%
on 01/15/21
+6.05 (+3.46%)
since 12/15/20
3-Month
150.52 +20.23%
on 10/30/20
182.00 -0.57%
on 01/15/21
+18.23 (+11.20%)
since 10/15/20
52-Week
112.03 +61.54%
on 03/23/20
182.00 -0.57%
on 01/15/21
+40.67 (+28.99%)
since 01/15/20

Most Recent Stories

More News
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

PFE : 36.70 (-0.14%)
MRNA : 129.65 (-0.05%)
LLY : 190.77 (+2.19%)
IBB : 161.71 (-0.10%)
CNCR : 34.65 (-1.00%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
FBT : 176.29 (+0.05%)
SBIO : 56.23 (-1.00%)
PBE : 76.14 (-0.12%)
BTEC : 63.68 (-0.75%)
ARKG : 107.96 (-1.23%)
BNTX : 101.59 (-4.02%)
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ALXN : 156.70 (+0.03%)
AZN : 51.34 (+0.10%)
PPH : 69.72 (+0.49%)
BBH : 180.97 (+0.53%)
FBT : 176.29 (+0.05%)
PJP : 76.12 (-0.12%)
PBE : 76.14 (-0.12%)
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
BTEC : 63.68 (-0.75%)
IDNA : 51.32 (-0.81%)
GERM : 35.82 (+0.67%)
How Will Biotech ETFs React to These Q3 Earnings Release?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

BIIB : 275.84 (-1.59%)
ALXN : 156.70 (+0.03%)
GILD : 63.33 (+1.49%)
AMGN : 245.49 (+1.58%)
IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain

Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
BTEC : 63.68 (-0.75%)
IDNA : 51.32 (-0.81%)
GERM : 35.82 (+0.67%)
Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
PBE : 76.14 (-0.12%)
ARKG : 107.96 (-1.23%)
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
PBE : 76.14 (-0.12%)
ARKG : 107.96 (-1.23%)
Top-Performing Biotech ETFs Amid the Coronavirus Crisis

The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
ARKG : 107.96 (-1.23%)
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

IBB : 161.71 (-0.10%)
XBI : 151.73 (-1.11%)
BBH : 180.97 (+0.53%)
FBT : 176.29 (+0.05%)
ARKG : 107.96 (-1.23%)
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial

AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.

IBB : 161.71 (-0.10%)
CNCR : 34.65 (-1.00%)
XBI : 151.73 (-1.11%)
PPH : 69.72 (+0.49%)
BBH : 180.97 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Fund Summary

The VanEck Vectors Biotech ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of...

See More

Key Turning Points

3rd Resistance Point 183.65
2nd Resistance Point 182.82
1st Resistance Point 181.90
Last Price 180.97
1st Support Level 180.15
2nd Support Level 179.32
3rd Support Level 178.40

See More

52-Week High 182.00
Last Price 180.97
Fibonacci 61.8% 155.27
Fibonacci 50% 147.01
Fibonacci 38.2% 138.76
52-Week Low 112.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar